Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A synthetic small molecule belonging to the quinazolinamine class of heterocyclic aromatic compounds. It is structurally characterized by a pyrrolo[3,2-f]quinazoline core substituted with a (1-ethyl-propyl) group at position 7 and diamino groups at positions 1 and 3. The compound has been studied as an experimental molecule and is not approved for clinical use. Its mechanism of action is not fully established in public sources; however, related pyrroloquinazolines are known to act as inhibitors of dihydrofolate reductase or protein kinases in some contexts. No clinical indications or marketed products are associated with this compound as of now[1][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 7-(1-ethyl-propyl)-7H-pyrrolo-[3,2-f]quinazoline-1,3-diamine.